Pharmacologists and Alzheimer disease therapy: to boldly go where no scientist has gone before

Bibliography

• Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 2010;362:329-44
   PubMed Web of Science ®Google Scholar
• Mayeux R. Clinical practice. Early Alzheimer's disease. N Engl J Med 2010;362:2194-201
   PubMedGoogle Scholar
• Seripa D, Panza F, Franceschi M, Non-apolipoprotein E and apolipoprotein E genetics of sporadic Alzheimer's disease. Ageing Res Rev 2009;8:214-36
   PubMed Web of Science ®Google Scholar
• Castellani RJ, Rolston RK, Smith MA. Alzheimer disease. Dis Mon 2010;56:484-546
   PubMed Web of Science ®Google Scholar
• Haass C, Schlossmacher MG, Hung AY, Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 1992;359:322-5
   PubMed Web of Science ®Google Scholar
• Shoji M, Golde TE, Ghiso J, Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science 1992;258:126-9
   PubMed Web of Science ®Google Scholar
• Seubert P, Vigo-Pelfrey C, Esch F, Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 1992;359:325-7
   PubMed Web of Science ®Google Scholar
• Marambaud P, Robakis NK. Genetic and molecular aspects of Alzheimer's disease shed light on new mechanisms of transcriptional regulation. Genes Brain Behav 2005;4:134-46
   PubMed Web of Science ®Google Scholar
• Galvan V, Gorostiza OF, Banwait S, Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664. Proc Natl Acad Sci USA 2006;103:7130-5
   PubMed Web of Science ®Google Scholar
• Park SA, Shaked GM, Bredesen DE, Mechanism of cytotoxicity mediated by the C31 fragment of the amyloid precursor protein. Biochem Biophys Res Commun 2009;388:450-5
   PubMed Web of Science ®Google Scholar
• Giuffrida ML, Caraci F, Pignataro B, Beta-amyloid monomers are neuroprotective. J Neurosci 2009;29:10582-7
   PubMed Web of Science ®Google Scholar
• Shankar GM, Li S, Mehta TH, Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008;14:837-42
   PubMed Web of Science ®Google Scholar
• Gotz J, Chen F, van Dorpe J, Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 2001;293:1491-5
   PubMed Web of Science ®Google Scholar
• Ballard C, Gauthier S, Corbett A, Alzheimer's disease. Lancet 2011;377:1019-31
   PubMed Web of Science ®Google Scholar
• Small SA, Duff K. Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron 2008;60:534-42
   PubMed Web of Science ®Google Scholar
• Robakis NK. Are Ab and its derivatives causative agents or innocent bystanders in AD? Neurodegener Dis 2010;7:32-7
   PubMed Web of Science ®Google Scholar
• Lukiw WJ, Cui JG, Yuan LY, Acyclovir or Abeta42 peptides attenuate HSV-1-induced miRNA-146a levels in human primary brain cells. Neuroreport 2010;21:922-7
   PubMed Web of Science ®Google Scholar
• Robakis NK. Mechanisms of AD neurodegeneration may be independent of Abeta and its derivatives. Neurobiol Aging 2011;32:372-9
   PubMed Web of Science ®Google Scholar
• Zubenko GS, Moossy J, Martinez AJ, Neuropathologic and neurochemical correlates of psychosis in primary dementia. Arch Neurol 1991;48:619-24
   PubMed Web of Science ®Google Scholar
• Hensley K, Carney JM, Mattson MP, A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc Natl Acad Sci USA 1994;91:3270-4
   PubMed Web of Science ®Google Scholar
• Butterfield DA, Galvan V, Lange MB, In vivo oxidative stress in brain of Alzheimer disease transgenic mice: requirement for methionine 35 in amyloid beta-peptide of APP. Free Radic Biol Med 2010;48:136-44
   PubMed Web of Science ®Google Scholar
• Maiti P, Lomakin A, Benedek GB, Despite its role in assembly, methionine 35 is not necessary for amyloid beta-protein toxicity. J Neurochem 2010;113:1252-62
   PubMed Web of Science ®Google Scholar
• Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 1997;23:134-47
   PubMed Web of Science ®Google Scholar
• Hensley K, Hall N, Subramaniam R, Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J Neurochem 1995;65:2146-56
   PubMed Web of Science ®Google Scholar
• Butterfield DA, Drake J, Pocernich C, Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol Med 200;7:548-54
   Google Scholar
• Butterfield DA, Sultana R. Redox proteomics identification of oxidatively modified brain proteins in Alzheimer's disease and mild cognitive impairment: insights into the progression of this dementing disorder. J Alzheimers Dis 2007;12:61-72
   PubMed Web of Science ®Google Scholar
• Sultana R, Poon HF, Cai J, Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach. Neurobiol Dis 2006;22:76-87
   PubMed Web of Science ®Google Scholar
• Sultana R, Perluigi M, Butterfield DA. Protein oxidation and lipid peroxidation in brain of subjects with Alzheimer's disease: insights into mechanism of neurodegeneration from redox proteomics. Antioxid Redox Signal 2006;8:2021-37
   PubMed Web of Science ®Google Scholar
• Sultana R, Boyd-Kimball D, Poon HF, Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD. Neurobiol Aging 2006;27:1564-76
   PubMed Web of Science ®Google Scholar
• Reed TT, Pierce WM Jr, Turner DM, Proteomic identification of nitrated brain proteins in early Alzheimer's disease inferior parietal lobule. J Cell Mol Med 2009;13:2019-29
   PubMed Web of Science ®Google Scholar
• Reed T, Perluigi M, Sultana R, Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease. Neurobiol Dis 2008;30:107-20
   PubMed Web of Science ®Google Scholar
• Perluigi M, Sultana R, Cenini G, Redox proteomics identification of 4-hydroxynonenal-modified brain proteins in Alzheimer's disease: role of lipid peroxidation in Alzheimer's disease pathogenesis. Proteomics Clin Appl 2009;3:682-93
   PubMed Web of Science ®Google Scholar
• Markesbery WR, Carney JM. Oxidative alterations in Alzheimer's disease. Brain Pathol 1999;9:133-46
   PubMed Web of Science ®Google Scholar
• Montine TJ, Markesbery WR, Morrow JD, Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease. Ann Neurol 1998;44:410-13
   PubMed Web of Science ®Google Scholar
• Montine TJ, Beal MF, Cudkowicz ME, Increased CSF F2-isoprostane concentration in probable AD. Neurology 1999;52:562-5
   PubMed Web of Science ®Google Scholar
• Greilberger J, Koidl C, Greilberger M, Malondialdehyde, carbonyl proteins and albumin-disulphide as useful oxidative markers in mild cognitive impairment and Alzheimer's disease. Free Radic Res 2008;42:633-8
   PubMed Web of Science ®Google Scholar
• Williams TI, Lynn BC, Markesbery WR, Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in Mild Cognitive Impairment and early Alzheimer's disease. Neurobiol Aging 2006;27:1094-9
   PubMed Web of Science ®Google Scholar
• Ansari MA, Scheff SW. Oxidative stress in the progression of Alzheimer disease in the frontal cortex. J Neuropathol Exp Neurol 2010;69:155-67
   PubMed Web of Science ®Google Scholar
• Roberts LJ II, Montine TJ, Markesbery WR, Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J Biol Chem 1998;273:13605-12
   PubMed Web of Science ®Google Scholar
• Mullaart E, Boerrigter ME, Ravid R, Increased levels of DNA breaks in cerebral cortex of Alzheimer's disease patients. Neurobiol Aging 1990;11:169-73
   PubMed Web of Science ®Google Scholar
• Gabbita SP, Lovell MA, Markesbery WR. Increased nuclear DNA oxidation in the brain in Alzheimer's disease. J Neurochem 1998;71:2034-40
   PubMed Web of Science ®Google Scholar
• Mecocci P, MacGarvey U, Beal MF. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol 1994;36:747-51
   PubMed Web of Science ®Google Scholar
• Wang J, Xiong S, Xie C, Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer's disease. J Neurochem 2005;93:953-62
   PubMed Web of Science ®Google Scholar
• Wang J, Markesbery WR, Lovell MA. Increased oxidative damage in nuclear and mitochondrial DNA in mild cognitive impairment. J Neurochem 2006;96:825-32
   PubMed Web of Science ®Google Scholar
• Ding Q, Markesbery WR, Chen Q, Ribosome dysfunction is an early event in Alzheimer's disease. J Neurosci 2005;25:9171-5
   PubMed Web of Science ®Google Scholar
• Lovell MA, Markesbery WR. Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer's disease. Nucleic Acids Res 2007;35:7497-504
   PubMed Web of Science ®Google Scholar
• Colurso GJ, Nilson JE, Vervoort LG. Quantitative assessment of DNA fragmentation and beta-amyloid deposition in insular cortex and midfrontal gyrus from patients with Alzheimer's disease. Life Sci 2003;73:1795-803
   PubMed Web of Science ®Google Scholar
• Sultana R, Banks WA, Butterfield DA. Decreased levels of PSD95 and two associated proteins and increased levels of BCl2 and caspase 3 in hippocampus from subjects with amnestic mild cognitive impairment: Insights into their potential roles for loss of synapses and memory, accumulation of Abeta, and neurodegeneration in a prodromal stage of Alzheimer's disease. J Neurosci Res 2010;88:469-77
   PubMed Web of Science ®Google Scholar
• Takuma K, Yan SS, Stern DM, Mitochondrial dysfunction, endoplasmic reticulum stress, and apoptosis in Alzheimer's disease. J Pharmacol Sci 2005;97:312-16
   PubMed Web of Science ®Google Scholar
• Bader Lange ML, Cenini G, Piroddi M, Loss of phospholipid asymmetry and elevated brain apoptotic protein levels in subjects with amnestic mild cognitive impairment and Alzheimer disease. Neurobiol Dis 2008;29:456-64
   PubMed Web of Science ®Google Scholar
• Ojaimi J, Byrne E. Mitochondrial function and alzheimer's disease. Biol Signals Recept 2001;10:254-62
   PubMedGoogle Scholar
• Butterfield DA, Gnjec A, Poon HF, Redox proteomics identification of oxidatively modified brain proteins in inherited Alzheimer's disease: an initial assessment. J Alzheimers Dis 2006;10:391-7
   PubMed Web of Science ®Google Scholar
• Jungsuwadee P, Cole MP, Sultana R, Increase in Mrp1 expression and 4-hydroxy-2-nonenal adduction in heart tissue of Adriamycin-treated C57BL/6 mice. Mol Cancer Ther 2006;5:2851-60
   PubMed Web of Science ®Google Scholar
• Butterfield DA, Poon HF, St Clair D, Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease. Neurobiol Dis 2006;22:223-32
   PubMed Web of Science ®Google Scholar
• Butterfield DA, Reed T, Perluigi M, Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment. Neurosci Lett 2006;397:170-3
   PubMed Web of Science ®Google Scholar
• Bezprozvanny I, Mattson MP. Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci 2008;31:454-63
   PubMed Web of Science ®Google Scholar
• Berridge MJ, Bootman MD, Lipp P. Calcium–a life and death signal. Nature 1998;395:645-8
   PubMed Web of Science ®Google Scholar
• Spat A, Szanda G, Csordas G, High- and low-calcium-dependent mechanisms of mitochondrial calcium signalling. Cell Calcium 2008;44:51-63
   Google Scholar
• Mattson MP, Cheng B, Davis D, beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 1992;12:376-89
   PubMed Web of Science ®Google Scholar
• Arispe N, Rojas E, Pollard HB. Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proc Natl Acad Sci USA 1993;90:567-71
   PubMed Web of Science ®Google Scholar
• Demuro A, Mina E, Kayed R, Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem 2005;280:17294-300
   PubMed Web of Science ®Google Scholar
• Lauderback CM, Hackett JM, Huang FF, The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Abeta1-42. J Neurochem 2001;78:413-16
   PubMed Web of Science ®Google Scholar
• Mark RJ, Pang Z, Geddes JW, Amyloid beta-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation. J Neurosci 1997;17:1046-54
   PubMed Web of Science ®Google Scholar
• Musiał A, Bajda M, Malawska B. Recent developments in cholinsterases inhibitors for Alzheimer's disease treatment. Curr Med Chem 2007;14:2654-79
   PubMed Web of Science ®Google Scholar
• Ibach B, Haen E. Acetylcholinesterase inhibition in Alzheimer's disease. Curr Pharm Des 2004;10:231-51
   PubMed Web of Science ®Google Scholar
• Geerts H, Grossberg GT. Pharmacology of acetylcholinsterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease. J Clin Pharmacol 2006;46:8S-16S
   PubMed Web of Science ®Google Scholar
• Cosman KM, Boyle LL, Porsteinsson AP. Memantine in the treatment of mild-to-moderate Alzheimer's disease. Expert Opin Pharmacother 2007;8:203-14
   PubMed Web of Science ®Google Scholar
• Sabbagh MN, Shill HA. Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea. Curr Opin Investig Drugs 2010;11:80-91
   PubMed Web of Science ®Google Scholar
• Lipton SA. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism. Curr Alzheimer Res 2005;2:155-65
   PubMedGoogle Scholar
• Martorana A, Esposito Z, Koch G. Beyond the cholinergic hypothesis: do current drugs work in Alzheimer's disease? CNS Neurosci Ther 2010;16:235-45
   PubMed Web of Science ®Google Scholar
• Benjamin B, Burns A. Donepezil for Alzheimer's disease. Expert Rev Neurother 2007;7:1243-9
   PubMed Web of Science ®Google Scholar
• Thomas SJ, Grossberg GT. Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias. Clin Interv Aging 2009;4:367-77
   PubMed Web of Science ®Google Scholar
• Hsiung GY, Feldman HH. Pharmacological treatment in moderate-to-severe Alzheimer's disease. Expert Opin Pharmacother 2008;9:2575-82
   PubMed Web of Science ®Google Scholar
• Cano SJ, Posner HB, Moline ML, The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts. J Neurol Neurosurg Psychiatry 2010;81:1363-8
   PubMed Web of Science ®Google Scholar
• Ashford JW. Screening for memory disorders, dementia and Alzheimer'disease. Aging Health 2008;4:399-432
   Google Scholar
• Joffres C, Graham J, Rockwood K. Qualitative analysis of the clinician interview-based impression of change (Plus): methodological issues and implications for clinical research. Int Psychogeriatr 2000;12:403-13
   PubMed Web of Science ®Google Scholar
• Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 2002;41:719-39
   PubMed Web of Science ®Google Scholar
• Takada-Takatori Y, Kume T, Izumi Y, Roles of nicotinic receptors in acetylcholinesterase inhibitor-induced neuroprotection and nicotinic receptor up-regulation. Biol Pharm Bull 2009;32:318-24
   PubMed Web of Science ®Google Scholar
• Burns A, Rossor M, Hecker J, The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord 1999;10:237-44
   PubMed Web of Science ®Google Scholar
• Homma A, Takeda M, Imai Y, Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group. Dement Geriatr Cogn Disord 2000;11:299-313
   PubMed Web of Science ®Google Scholar
• Rogers SL, Doody RS, Mohs RC, Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998;158:1021-31
   PubMed Web of Science ®Google Scholar
• Rogers SL, Farlow MR, Doody RS, A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998;50:136-45
   PubMed Web of Science ®Google Scholar
• Mohs RC, Doody RS, Morris JC, A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001;57:481-8
   PubMed Web of Science ®Google Scholar
• Winblad B, Engedal K, Soininen H, A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001;57:489-95
   PubMed Web of Science ®Google Scholar
• Feldman H, Gauthier S, Hecker J, A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001;57:613-20
   PubMed Web of Science ®Google Scholar
• Feldman H, Gauthier S, Hecker J, Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial. Int J Geriatr Psychiatry 2005;20:559-69
   PubMed Web of Science ®Google Scholar
• Jelic V, Haglund A, Kowalski J, Donepezil treatment of severe Alzheimer's disease in nursing home settings. A responder analysis. Dement Geriatr Cogn Disord 2008;26:458-66
   PubMed Web of Science ®Google Scholar
• Winblad B, Kilander L, Eriksson S, Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group,placebo-controlled study. Lancet 2006;367:1057-65
   PubMed Web of Science ®Google Scholar
• Black SE, Doody R, Li H, Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 2007;69:459-69
   PubMed Web of Science ®Google Scholar
• Winblad B, Black SE, Homma A, Donepezil treatment in severe Alzheimer's disease: a pooled analysis of three clinical trials. Curr Med Res Opin 2009;25:2577-87
   PubMed Web of Science ®Google Scholar
• Feldman HH, Doody RS, Kivipelto M, Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 2010;74:956-64
   PubMed Web of Science ®Google Scholar
• Birks J, Grimley Evans J, Iakovidou V, Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev 2009;2:CD001191
   PubMed Web of Science ®Google Scholar
• Rosler M, Anand R, Cicin-Sain A, Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999;318:633-8
   PubMed Web of Science ®Google Scholar
• Farlow M, Anand R, Messina J Jr, A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol 2000;44:236-41
   PubMed Web of Science ®Google Scholar
• Burns A, Spiegel R, Quarg P. Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. Int J Geriatr Psychiatry 2004;19:243-9
   PubMed Web of Science ®Google Scholar
• Lefevre G, Sedek G, Huang HL, Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application. J Clin Pharmacol 2007;47:471-8
   PubMed Web of Science ®Google Scholar
• Emre M, Bernabei R, Blesa R, Drug profile: transdermal rivastigmine patch in the treatment of Alzheimer disease. CNS Neurosci Ther 2010;16:246-53
   PubMed Web of Science ®Google Scholar
• Winblad B, Cummings J, Andreasen N, A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease–rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007;22:456-67
   PubMed Web of Science ®Google Scholar
• Winblad B, Grossberg G, Frolich L, IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 2007;69:S14-22
   Web of Science ®Google Scholar
• Sadowsky CH, Farlow MR, Meng X, Safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched from donepezil: data from three clinical trials. Int J Clin Pract 2010;64:188-93
   PubMed Web of Science ®Google Scholar
• Cummings JL, Ferris SH, Farlow MR, Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: a retrospective analysis. Dement Geriatr Cogn Disord 2010;29:406-12
   PubMed Web of Science ®Google Scholar
• Cummings JL, Farlow MR, Meng X, Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease. Clin Drug Investig 2010;30:41-9
   PubMed Web of Science ®Google Scholar
• Tariot PN, Solomon PR, Morris JC, A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000;54:2269-76
   PubMed Web of Science ®Google Scholar
• Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomized controlled trial. Galantamine International-1 Study Group. BMJ 2000;321:1445-9
   PubMed Web of Science ®Google Scholar
• Raskind MA, Peskind ER, Wessel T, Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000;54:2261-8
   PubMed Web of Science ®Google Scholar
• Aronson S, Van Baelen B, Kavanagh S, Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial. Drugs Aging 2009;26:231-9
   PubMed Web of Science ®Google Scholar
• Burns A, Bernabei R, Bullock R, Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial. Lancet Neurol 2009;8:39-47
   PubMed Web of Science ®Google Scholar
• McKeage K. Memantine: a review of its use in moderate to severe Alzheimer's disease. CNS Drugs 2009;23:881-97
   PubMed Web of Science ®Google Scholar
• Rossom R, Adityanjee Dysken M. Efficacy and tolerability of memantine in the treatment of dementia. Am J Geriatr Pharmacother 2004;2:303-12
   PubMedGoogle Scholar
• Reisberg B, Doody R, Stoffler A, Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348:1333-41
   PubMed Web of Science ®Google Scholar
• Tariot PN, Farlow MR, Grossberg GT, Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004;291:317-24
   PubMed Web of Science ®Google Scholar
• van Dyck CH, Tariot PN, Meyers B, For the Memantine MEM-MD-01 Study Group. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord 2007;21:136-43
   PubMed Web of Science ®Google Scholar
• Modrego PJ, Fayed N, Errea JM, Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy. Eur J Neurol 2010;17:405-12
   PubMed Web of Science ®Google Scholar
• Schneider LS, Dagerman KS, Higgins JP, Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol 2011; [Epub ahead of print]
   Web of Science ®Google Scholar
• Farlow MR, Alva G, Meng X, A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis. Curr Med Res Opin 2010;26:263-9
   PubMed Web of Science ®Google Scholar
• Olin JT, Bhatnagar V, Reyes P, Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32). Int J Geriatr Psychiatry 2010;25:419-26
   PubMed Web of Science ®Google Scholar
• Galenko-Iaroshevskii PA, Shadurskii KS, Il'iuchenok TI, Anti-allergic properties of dimebon, fencarol and ketotifen in sensitization by common ragweed pollen. Farmakol Toksikol 1984;47:75-8
   PubMedGoogle Scholar
• Kiseleva EE, Zakharevskii AS, Nikiforova IN. The anti-allergic activity and mechanism of action of gamma-carboline derivatives. Farmakol Toksikol 1990;53:22-4
   PubMedGoogle Scholar
• Bachurin S, Bukatina E, Lermontova N, Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer. Ann NY Acad Sci 2001;939:425-35
   PubMed Web of Science ®Google Scholar
• Bachurin SO, Shevtsova EP, Kireeva EG, Mitochondria as a target for neurotoxins and neuroprotective agents. Ann NY Acad Sci 2003;993:334-44
   PubMed Web of Science ®Google Scholar
• Lermontova NN, Redkozubov AE, Shevtsova EF, Dimebon and tacrine inhibit neurotoxic action of beta-amyloid in culture and block L-type Ca(2+) channels. Bull Exp Biol Med 2001;132:1079-83
   PubMed Web of Science ®Google Scholar
• Doody RS, Gavrilova SI, Sano M, Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet 2008;372:207-15
   PubMed Web of Science ®Google Scholar
• Jones RW. Dimebon disappointment. Alzheimers Res Ther 2010;2:25
   PubMed Web of Science ®Google Scholar
• Lippiello P, Letchworth SR, Gatto GJ, Ispronicline: a novel alpha4beta2 nicotinic acetylcholine receptor-selective agonist with cognition-enhancing and neuroprotective properties. J Mol Neurosci 2006;30:19-20
   PubMed Web of Science ®Google Scholar
• Dunbar G, Demazieres A, Monreal A, Pharmacokinetics and safety profile of ispronicline (TC-1734), a new brain nicotinic receptor partial agonist, in young healthy male volunteers. J Clin Pharmacol 2006;46:715-26
   PubMed Web of Science ®Google Scholar
• Rezvani AH, Kholdebarin E, Brucato FH, Effect of R3487/MEM3454, a novel nicotinic alpha7 receptor partial agonist and 5-HT3 antagonist on sustained attention in rats. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:269-75
   PubMed Web of Science ®Google Scholar
• Available from: http://www.memorypharma.com [Last accessed 21 February 2006]
   Google Scholar
• Available from: http://www.memorypharma.com [Last accessed 2 November 2007]
   Google Scholar
• Hilt D, Gawril M, Koenig G, ICAD 2009 Conference, Vienna, Austria, July 11-16, 2009. Available from: http://www.envivopharma.com/library/user_files/Hilt_etal_A7_ICAD2009.pdf [Last accessed 12 February 2011]
   Google Scholar
• Available from: http://www.envivopharma.com [Last accessed 11 May 2010]
   Google Scholar
• Skolnick P, Popik P, Trullas R. Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci 2009;30:563-9
   PubMed Web of Science ®Google Scholar
• Available from: http://www.evotec.com [Last accessed 28 mar 2008]
   Google Scholar
• Available from: http://www.evotec.com [Last accessed 3 Jul 2008]
   Google Scholar
• Jhee SS, Chappell AS, Zarotsky V, Multiple-dose plasma pharmacokinetic and safety study of LY450108 and LY451395 (AMPA receptor potentiators) and their concentration in cerebrospinal fluid in healthy human subjects. J Clin Pharmacol 2006;46:424-32
   PubMed Web of Science ®Google Scholar
• Chappell AS, Gonzales C, Williams J, AMPA potentiator treatment of cognitive deficits in Alzheimer disease. Neurology 2007;68:1008-12
   PubMed Web of Science ®Google Scholar
• Yi P, Hadden C, Kulanthaivel P, Disposition and metabolism of semagacestat, a {gamma}-secretase inhibitor, in humans. Drug Metab Dispos 2010;38:554-65
   PubMed Web of Science ®Google Scholar
• Siemers ER, Quinn JF, Kaye J, Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 2006;66:602-4
   PubMed Web of Science ®Google Scholar
• Fleisher AS, Raman R, Siemers ER, Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol 2008;65:1031-8
   PubMed Web of Science ®Google Scholar
• Extance A. Alzheimer's failure raises questions about disease-modifying strategies. Nat Rev Drug Discov 2010;9:749-51
   PubMed Web of Science ®Google Scholar
• Galasko DR, Graff-Radford N, May S, Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals. Alzheimer Dis Assoc Disord 2007;21:292-9
   PubMed Web of Science ®Google Scholar
• Wilcock GK, Black SE, Hendrix SB, Tarenflurbil Phase II Study investigators. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol 2008;7:483-93
   PubMed Web of Science ®Google Scholar
• Green RC, Schneider LS, Amato DA, Tarenflurbil Phase 3 Study Group. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 2009;302:2557-64
   PubMed Web of Science ®Google Scholar
• Seubert P, Barbour R, Khan K, Antibody capture of soluble Abeta does not reduce cortical Abeta amyloidosis in the PDAPP mouse. Neurodegener Dis 2008;5:65-71
   PubMed Web of Science ®Google Scholar
• Kerchner GA, Boxer AL. Bapineuzumab. Expert Opin Biol Ther 2010;10:1121-30
   PubMed Web of Science ®Google Scholar
• Rinne JO, Brooks DJ, Rossor MN, 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010;9:363-72
   PubMed Web of Science ®Google Scholar
• Black RS, Sperling RA, Safirstein B, A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 2010;24:198-203
   PubMed Web of Science ®Google Scholar
• Raskind M, Liang E, Sperling R, ICAD 2009 Conference, Vienna, Austria, July 11-16, 2009. Available from: http://www.abstractsonline.com/plan/ViewAbstract.aspx?sKey=ca162e8d-9178-41b0-bf96-04216f4d1083&cKey=af781608-6f44-4030-a5ab-6db76ef92f46 [Last accessed 14 February 2011]
   Google Scholar
• Salloway S, Sperling R, Gilman S, Bapineuzumab 201 Clinical Trial Investigators. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009;73:2061-70
   PubMed Web of Science ®Google Scholar
• Ronald B, DeMattos RB, Margaret M, Identification, characterization, and comparison of amino-terminally truncated Abeta42 peptides in Alzheimer's disease brain tissue and in plasma from Alzheimer's patients receiving solanezumab immunotherapy treatment. Alzheimers Dement 2009;5:P156-7
   Google Scholar
• Siemers ER, Friedrich S, Dean RA, Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol 2010;33:67-73
   PubMed Web of Science ®Google Scholar
• Available from: http://www.adisinsight.com [Last accessed 20 June 2011]
   Google Scholar
• Vasiliou S. 12th international conference on Alzheimer's disease (ICAD) 2009: emerging therapeutic strategies, diagnostic techniques and imaging technologies for AD. Drugs Future 2009;34:587-97
   Google Scholar
• Available from: http://clinicaltrials.gov/ct2/show/NCT01224106 [Last accessed 15 February 2011]
   Google Scholar
• Wischik CM, Edwards PC, Lai RY, Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci USA 1996;93:11213-18
   PubMed Web of Science ®Google Scholar
• Medina DX, Caccamo A, Oddo S. Methylene blue reduces abeta levels and rescues early cognitive deficit by increasing proteasome activity. Brain Pathol 2011;21:140-9
   PubMed Web of Science ®Google Scholar
• Gozes I, Steingart RA, Spier AD. NAP mechanisms of neuroprotection. J Mol Neurosci 2004;24:67-72
   PubMed Web of Science ®Google Scholar
• Gozes I, Divinski I, Piltzer I. NAP and D-SAL: neuroprotection against the beta amyloid peptide (1-42). BMC Neurosci 2008;9(Suppl 3):S3
   PubMedGoogle Scholar
• Matsuoka Y, Jouroukhin Y, Gray AJ, A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther 2008;325:146-53
   PubMed Web of Science ®Google Scholar
• Vulih-Shultzman I, Pinhasov A, Mandel S, Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model. J Pharmacol Exp Ther 2007;323:438-49
   PubMed Web of Science ®Google Scholar
• Matsuoka Y, Gray AJ, Hirata-Fukae C, Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J Mol Neurosci 2007;31:165-70
   PubMed Web of Science ®Google Scholar
• Ashur-Fabian O, Segal-Ruder Y, Skutelsky E, The neuroprotective peptide NAP inhibits the aggregation of the beta-amyloid peptide. Peptides 2003;24:1413-23
   PubMed Web of Science ®Google Scholar
• Available from: http://www.allontherapeutics.com [Last accessed 07 March 2007]
   Google Scholar
• Mohler EG, Shacham S, Noiman S, PRX- 03140, A novel 5-HT4 agonist, enhances memory and increases hippocampal acetylcholine efflux. Program No. 653.10. 2005 Abstract Viewer/Itinerary Planner. Society for Neuroscience; Washington, DC: 2005
   Google Scholar
• Granholm AE, Umphlet C, Moore AB, Effects of PRX-03140, a serotonin 5- HT4 receptor partial agonist, on cognition and growth factor levels in the aged rat Program No. 656.6. 2005 Abstract Viewer/Itinerary Planner. Society for Neuroscience; Washington, DC: 2005
   Google Scholar
• Shachem S. PRX-03140: A Novel 5-HT4 Partial Agonist with a Dual Cholinergic/Disease-Modifying Mechanism for the Treatment of Alzheimer Disease. 10th International Conference on Alzheimer's Disease (ICAD) July 14-20, 2006; Madrid, Spain
   Google Scholar
• Available from: http://www.findarticles.com [Last accessed 4 March 2005]
   Google Scholar
• Available from: http://www.adisinsight.com [Last accessed 14 September 2010]
   Google Scholar
• Childers WE Jr, Abou-Gharbia MA, Kelly MG, Synthesis and biological evaluation of benzodioxanylpiperazine derivatives as potent serotonin 5-HT(1A) antagonists: the discovery of Lecozotan. J Med Chem 2005;48:3467-70
   PubMed Web of Science ®Google Scholar
• Schechter LE, Smith DL, Rosenzweig-Lipson S, Lecozotan (SRA-333): a selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties. J Pharmacol Exp Ther 2005;314:1274-89
   PubMed Web of Science ®Google Scholar
• Patat A, Parks V, Raje S, Safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple doses of lecozotan in healthy young and elderly subjects. Br J Clin Pharmacol 2009;67:299-308
   PubMed Web of Science ®Google Scholar
• Raje S, Patat AA, Parks V, A positron emission tomography study to assess binding of lecozotan, a novel 5-hydroxytryptamine-1A silent antagonist, to brain 5-HT1A receptors in healthy young and elderly subjects, and in patients with Alzheimer's disease. Clin Pharmacol Ther 2008;83:86-96
   PubMed Web of Science ®Google Scholar
• Bishop KM, Hofer EK, Mehta A, Therapeutic potential of CERE-110 (AAV2-NGF): targeted, stable, and sustained NGF delivery and trophic activity on rodent basal forebrain cholinergic neurons. Exp Neurol 2008;211:574-84
   PubMed Web of Science ®Google Scholar
• Mandel RJ. CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer's disease. Curr Opin Mol Ther 2010;12:240-7
   PubMed Web of Science ®Google Scholar
• Hefti F. Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transections. J Neurosci 1986;6:2155-62
   PubMed Web of Science ®Google Scholar
• Fischer W, Wictorin K, Bjorklund A, Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature 1987;329:65-8
   PubMed Web of Science ®Google Scholar
• Tuszynski MH, Thal L, Pay M, A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005;11:551-5
   PubMed Web of Science ®Google Scholar
• Available from: http://www.adisinsight.com [Last accessed 20 June 2011]
   Google Scholar
• Rockenstein E, Mante M, Adame A, Effects of Cerebrolysin on neurogenesis in an APP transgenic model of Alzheimer's disease. Acta Neuropathol 2007;113:265-75
   PubMed Web of Science ®Google Scholar
• Alvarez XA, Cacabelos R, Laredo M, A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease. Eur J Neurol 2006;13:43-54
   PubMed Web of Science ®Google Scholar
• Muresanu DF, Rainer M, Moessler H. Improved global function and activities of daily living in patients with AD: a placebo-controlled clinical study with the neurotrophic agent Cerebrolysin. J Neural Transm Suppl 2002;62:277-85
   PubMedGoogle Scholar
• Ruther E, Ritter R, Apecechea M, Efficacy of the peptidergic nootropic drug cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT). Pharmacopsychiatry 1994;27:32-40
   PubMed Web of Science ®Google Scholar
• Xiao S, Yan H, Yao P. Efficay of FPF 1070 (Cerebrolysin) in Patients with Alzheimer's disease: a Multicentre, Randomised, Double-Blind, Placebo-Controlled Trial. Clin Drug Invest 2000;19:43-53
   Web of Science ®Google Scholar
• Wei ZH, He QB, Wang H, Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer's disease. J Neural Transm 2007;114:629-34
   PubMed Web of Science ®Google Scholar
• Barone E, Cenini G, Di Domenico F, Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: a novel mechanism of action. Pharmacol Res 2011;63:172-80
   PubMed Web of Science ®Google Scholar
• Murphy MP, Morales J, Beckett TL, Changes in cognition and amyloid-beta processing with long term cholesterol reduction using atorvastatin in aged dogs. J Alzheimers Dis 2010;22:135-50
   PubMed Web of Science ®Google Scholar
• McGuinness B, O'Hare J, Craig D, Statins for the treatment of dementia. Cochrane Database Syst Rev 2010;8:CD007514
   PubMed Web of Science ®Google Scholar
• Butterfield DA, Bader Lange ML, Sultana R. Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease. Biochim Biophys Acta 2010;1801:924-9
   PubMed Web of Science ®Google Scholar
• Golde TE, Schneider LS, Koo EH. Anti-abeta therapeutics in Alzheimer's disease: the need for a paradigm shift. Neuron 2011;69:203-13
   PubMed Web of Science ®Google Scholar
• Citron M. Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov 2010;9:387-98
   PubMed Web of Science ®Google Scholar